Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. See manufacturer's labeling.• Commercially-prepared premixed infusion: Contains the excipient cyclodextrin (sulfobutyl ether beta-cyclodextrin), which may accumulate in patients with renal insufficiency, although the clinical significance of this finding is uncertain (Luke 2010).• Long-term use: There has been limited experience in patients receiving IV amiodarone for >3 weeks.• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). If you were a clever pharmaceutical marketer, what would you name a drug that helps pace the heart? Fosamprenavir: May increase the serum concentration of Amiodarone.Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Fosnetupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Fosphenytoin: May decrease the serum concentration of Amiodarone. Management: Consider using a non-interacting statin (eg, pravastatin, pitavastatin) in patients on amiodarone. Dilute to final concentration of 1 to 6 mg/mL. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. (ABSTRACT TRUNCATED AT 400 WORDS) Publication types QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of RisperiDONE.

If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Specifically, desethylamiodarone concentrations may decrease.

Note: Half-life is shortened in children vs adults. When amiodarone is discontinued, increase the talazoparib dose to the dose used before initiation of amiodarone after 3 to 5 times the half-life of amiodarone.Tegaserod: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod. Management: Consider alternatives to this combination. Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.Domperidone: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Domperidone.

Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax. Corneal microdeposits occur in a majority of adults and may cause visual disturbances in up to 10% of patients (blurred vision, halos); asymptomatic microdeposits may be reversible and are not generally considered a reason to discontinue treatment. Change to oral maintenance dose when clinically indicated (AHA/ACC/HRS [January 2014]).Oral: 600 to 800 mg daily in divided doses for a total load of up to 10 g, then a maintenance dose of 200 mg once daily (AHA/ACC/HRS [January 2014]) Preoperative regimen: 150 mg once, followed by 0.4 mg/Postoperative regimen: Starting at postoperative recovery: 1 g infused over 24 hours for 2 days (Guarnieri 1999).Postoperative regimen: IV: Starting 6 hours postoperatively, 1,050 mg IV loading dose over 24 hours, followed by 400 mg orally 3 times daily on postop days 1 through 4 (White 2003).Oral: 200 mg 3 times daily for 7 days prior to surgery, followed by 200 mg daily until hospital discharge (Daoud 1997).IV: Initial: 300 mg over 1 hour, then 10 to 50 mg/hour over 24 hours followed by an oral maintenance dose (AHA/ACC/HRS [January 2014]). If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Time to Peak. Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Management: Consider triazolam dose reduction in patients receiving concomitant weak CYP3A4 inhibitors.Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant. 2018 Nov 7;36(1):3. doi: 10.1007/s11095-018-2541-z.Case Rep Cardiol. Thyroid nodules and/or thyroid cancer have also been reported. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.Piperaquine: QT-prolonging Agents (Highest Risk) may enhance the QTc-prolonging effect of Piperaquine. Management: Consider alternatives to this drug combination. Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).Erythromycin (Systemic): Amiodarone may enhance the QTc-prolonging effect of Erythromycin (Systemic). Myocardium/plasma ratios of amiodarone are high both in man and in animals; peak concentrations in the myocardium are reached within half an hour after administration of an intravenous bolus to dogs.